Axon Enterprise (NASDAQ:AXON) Rating Reiterated by JMP Securities

Axon Enterprise (NASDAQ:AXON)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a report released on Monday, Benzinga reports. They presently have a $375.00 target price on the biotechnology company’s stock. JMP Securities’ price objective points to a potential upside of 4.36% from the stock’s previous close.

A number of other analysts have also weighed in on AXON. Northland Securities upped their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Barclays lifted their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a report on Wednesday, August 7th. Craig Hallum boosted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Robert W. Baird lifted their price objective on shares of Axon Enterprise from $355.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average target price of $361.15.

Axon Enterprise Trading Down 1.4 %

AXON opened at $359.35 on Monday. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The firm has a market cap of $27.16 billion, a P/E ratio of 105.07, a P/E/G ratio of 9.50 and a beta of 0.94. Axon Enterprise has a 52 week low of $189.12 and a 52 week high of $378.89. The business has a fifty day simple moving average of $334.23 and a 200-day simple moving average of $312.76.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same period in the prior year, the firm earned $0.80 earnings per share. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. On average, equities analysts expect that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the sale, the director now owns 7,379 shares in the company, valued at approximately $2,752,588.37. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now owns 7,379 shares in the company, valued at approximately $2,752,588.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joshua Isner sold 25,811 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the transaction, the president now owns 228,166 shares in the company, valued at $82,103,253.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 312,643 shares of company stock worth $113,637,859. 6.10% of the stock is owned by insiders.

Institutional Trading of Axon Enterprise

Hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new position in Axon Enterprise during the fourth quarter worth about $195,406,000. Motley Fool Asset Management LLC lifted its holdings in shares of Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after buying an additional 346,838 shares during the period. 1832 Asset Management L.P. purchased a new stake in shares of Axon Enterprise in the first quarter valued at approximately $81,630,000. Vanguard Group Inc. grew its holdings in Axon Enterprise by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock worth $2,547,878,000 after acquiring an additional 212,401 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Axon Enterprise by 110.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock worth $71,302,000 after acquiring an additional 144,568 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.